Juvenescence
Juvenescence Limited is a British Virgin Islands-based holding company focused on investing in the field of human aging and longevity. With a commitment to developing therapeutics that aim to extend both lifespan and healthspan, Juvenescence has raised significant funding to create a comprehensive ecosystem targeting aging and age-related diseases. The company collaborates with leading scientists and research institutions to in-license compounds and form joint ventures, leveraging recent scientific advancements to produce evidence-based therapies. By addressing the biological causes of aging, Juvenescence aims to develop medical solutions that promote healthy aging, metabolic health, and brain health. Their efforts are positioned to have substantial implications across various sectors, including healthcare and insurance, as they seek to improve the quality of life for an aging population.
LyGenesis, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, focused on organ regeneration technology. Founded in 2017, the company develops a platform that utilizes a patient's lymph nodes as bioreactors to regrow ectopic organs. Its primary target is liver regeneration, specifically aimed at aiding patients with end-stage liver disease. The technology enables the transplantation of donor cells through outpatient endoscopic ultrasound, facilitating the growth of functioning organs within the patient's body. In addition to liver regeneration, LyGenesis is exploring therapeutic applications for other organs, including the thymus, pancreas, and kidney.
LyGenesis, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, focused on organ regeneration technology. Founded in 2017, the company develops a platform that utilizes a patient's lymph nodes as bioreactors to regrow ectopic organs. Its primary target is liver regeneration, specifically aimed at aiding patients with end-stage liver disease. The technology enables the transplantation of donor cells through outpatient endoscopic ultrasound, facilitating the growth of functioning organs within the patient's body. In addition to liver regeneration, LyGenesis is exploring therapeutic applications for other organs, including the thymus, pancreas, and kidney.
Private Equity Round in 2018
AgeX Therapeutics is a biotechnology company dedicated to developing innovative therapeutics aimed at addressing human aging and degenerative diseases. The company utilizes its proprietary technologies, including telomerase-mediated cell immortality and induced Tissue Regeneration (iTR), to create potential treatments for age-related conditions. Its primary candidates in development include AGEX-BAT1, a cell therapy targeting metabolic disorders such as Type II diabetes, and AGEX-VASC1, designed to restore vascular support in ischemic tissues. Additionally, AgeX is advancing AGEX-iTR1547, a drug formulation intended to enhance regenerative capabilities in aged tissues. The company also offers human embryonic stem cells and tools for genomic interpretation through its GeneCards Database Suite. AgeX collaborates with research institutions, including the University of California, Irvine, on projects related to neurological disorders. Founded in 2017 and based in Alameda, California, AgeX aims to tackle significant challenges in the field of aging and regenerative medicine.
Private Equity Round in 2018
AgeX Therapeutics is a biotechnology company dedicated to developing innovative therapeutics aimed at addressing human aging and degenerative diseases. The company utilizes its proprietary technologies, including telomerase-mediated cell immortality and induced Tissue Regeneration (iTR), to create potential treatments for age-related conditions. Its primary candidates in development include AGEX-BAT1, a cell therapy targeting metabolic disorders such as Type II diabetes, and AGEX-VASC1, designed to restore vascular support in ischemic tissues. Additionally, AgeX is advancing AGEX-iTR1547, a drug formulation intended to enhance regenerative capabilities in aged tissues. The company also offers human embryonic stem cells and tools for genomic interpretation through its GeneCards Database Suite. AgeX collaborates with research institutions, including the University of California, Irvine, on projects related to neurological disorders. Founded in 2017 and based in Alameda, California, AgeX aims to tackle significant challenges in the field of aging and regenerative medicine.
LyGenesis, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, focused on organ regeneration technology. Founded in 2017, the company develops a platform that utilizes a patient's lymph nodes as bioreactors to regrow ectopic organs. Its primary target is liver regeneration, specifically aimed at aiding patients with end-stage liver disease. The technology enables the transplantation of donor cells through outpatient endoscopic ultrasound, facilitating the growth of functioning organs within the patient's body. In addition to liver regeneration, LyGenesis is exploring therapeutic applications for other organs, including the thymus, pancreas, and kidney.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.